Polyphenols in red wine and green tea halt prostate cancer growth
June 9, 2010; FASEB
In what could lead to a major advance in the treatment of prostate
cancer, scientists now know exactly why polyphenols in red wine and
green tea inhibit cancer growth.
more >>
|
Desperately Seeking Cures
May 15, 2010: Newsweek
How the road from
promising scientific breakthrough to real-world remedy has become all
but a dead end .
more >>
|
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
June 7, 2010: Yahoo! Finance
Pancreatic Cancer-Specific Radiolabeled Antibody Combined With
Low-Dose Gemcitabine Chemotherapy Continues to Provide Evidence of
Activity in Phase Ib/II Clinical Trial .
more >>
|
Momentum is gaining in Tucson on promising early-stage companies
April 17, 2010; Inside Tuscon Business
Amplimed Corporation has created a new cancer drug with early evidence
of effectiveness and low levels of toxicity.
more >>
|
ABRAXANEŽ in Combination with Gemcitabine Increases Survival in First-Line Treatment of Advanced Pancreatic Cancer
April 18, 2010; Fierce Biotech
Abraxis BioScience, Inc. announced updated overall survival findings from a phase
I/II study of ABRAXANE that given in combination with
gemcitabine, demonstrated increased survival of the first-line treatment
of patients with advanced pancreatic cancer
.
more >>
|
FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
April 16, 2010; Fierce Biotech
Genentech, Inc. announced today that the FDA approved the daily pill Tarceva as a maintenance treatment for patients with locally
advanced or metastatic non-small cell lung cancer.
more >>
|
Decoupling Is for Real and Biotech Is the Next Bubble
April 15, 2010; Yahoo! Finance
True to his bearish position of the last few years, John Mauldin is not jumping on the bull market bandwagon
.
more >>
|
Cancer Vaccines May Be On The Verge Of Wider Use
April 7, 2010; Pharma Live
One of the persistent frustrations in cancer treatment has been the way
that tumors can evade our immune systems as they grow and multiply
inside our bodies.
more >>
|
BioSante Announces FDA Orphan Drug Designation for GVAX Pancreatic Cancer Vaccine
March 15, 2010; Fierce Biotech
The Orphan Drug designation of GVAX Pancreas Vaccine for the treatment
of pancreatic cancer is BioSante's first GVAX regulatory submission and
response from the FDA since acquiring this portfolio of cancer vaccines
last October.
more >>
|
FDA Grants Orphan Status to Clavis Pharma's Pancreatic Cancer Drug
Friday, January 8 2010; Therapeutics Daily
Norwegian firm Clavis Pharma ASA (OSL: CLAVIS) said today that its drug candidate Intravenous CP-4126 has been granted Orphan Drug Designation for the treatment of pancreatic cancer by the US Food and Drug Administration (FDA).
more >>
|
|
